Crucell N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
15 okt 2007 - 08:01
Statutaire naam
Crucell N.V.
Titel
MEDIMMUNE AND CRUCELL ANNOUNCE COLLABORATION TO DEVELOP NEW ANTIBODIES FOR THE TREATMENT AND PREVENTION OF HOSPITAL-ACQUIRED BACTERIAL INFECTION
Bericht
Gaithersburg, MD, USA and Leiden, The Netherlands - October 15, 2007 – MedImmune and Crucell N.V. (Euronext, NASDAQ: CRXL) announced today that they have entered into an exclusive license and research collaboration to further develop and commercialize one of Crucell’s panels of bacterial antibodies primarily for the treatment and prevention of hospital-acquired bacterial infection.
Under the agreement, MedImmune is to provide Crucell certain upfront, annual and milestone payments potentially exceeding US$ 40 million, plus research and development (R&D) funding and an undisclosed royalty on product sales.
Under the terms of the agreement, Crucell has granted MedImmune an exclusive license to research, develop and commercialize antibodies within one of its MAbstract®-technology programs. In addition MedImmune will have access to Crucell’s antibody capabilities for further R&D.
The partnership combines Crucell’s unique antibody discovery, research and development capabilities with MedImmune’s expertise in clinical development and commercialization of anti-infective antibodies.
In 2005, Crucell announced the initiation of several new antibody discovery programs in the field of hospital-acquired infections. Under the terms of the license agreement announced today, Crucell has now entered into a partnership with MedImmune for one of these programs. Crucell has discovered and developed these unique anti-bacterial antibodies using its proprietary MAbstract® technology.
“As a company strongly committed to the prevention of infectious disease, we are excited to expand our research to include a broader program in bacterial infection through this collaboration with Crucell,” said JoAnn Suzich, Ph.D., MedImmune’s senior director, infectious disease research.
“We are confident that this collaboration will accelerate the development of this urgently needed therapeutic to circumvent antibiotic resistant infections and we are immensely proud that MedImmune, a leader and innov
Gerelateerde downloads
Datum laatste update: 27 september 2024